National Health Investors, Inc. $NHI Shares Bought by Hsbc Holdings PLC

Hsbc Holdings PLC increased its position in National Health Investors, Inc. (NYSE:NHI) by 12.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,520 shares of the real estate investment trust’s stock after purchasing an additional 9,094 shares during the quarter. Hsbc Holdings PLC owned 0.17% of National Health Investors worth $6,834,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of National Health Investors in the fourth quarter worth about $55,301,000. Freestone Grove Partners LP acquired a new stake in National Health Investors during the 4th quarter valued at approximately $21,869,000. Adage Capital Partners GP L.L.C. purchased a new stake in National Health Investors during the 4th quarter worth approximately $19,856,000. Balyasny Asset Management L.P. increased its holdings in National Health Investors by 66.9% during the 2nd quarter. Balyasny Asset Management L.P. now owns 614,960 shares of the real estate investment trust’s stock worth $43,121,000 after purchasing an additional 246,486 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of National Health Investors by 481.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 236,383 shares of the real estate investment trust’s stock valued at $18,792,000 after purchasing an additional 195,716 shares in the last quarter. Institutional investors and hedge funds own 62.51% of the company’s stock.

Insider Transactions at National Health Investors

In other National Health Investors news, CEO D. Eric Mendelsohn acquired 1,500 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were purchased at an average price of $68.84 per share, with a total value of $103,260.00. Following the completion of the transaction, the chief executive officer owned 133,316 shares in the company, valued at $9,177,473.44. The trade was a 1.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Robert A. Mccabe, Jr. purchased 890 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were acquired at an average price of $71.65 per share, for a total transaction of $63,768.50. Following the acquisition, the director directly owned 44,159 shares in the company, valued at $3,163,992.35. This represents a 2.06% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 2.70% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft decreased their target price on National Health Investors from $85.00 to $80.00 and set a “hold” rating for the company in a research report on Thursday, June 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $94.00 price objective on shares of National Health Investors in a report on Wednesday, April 22nd. Truist Financial lowered their target price on shares of National Health Investors from $89.00 to $81.00 and set a “buy” rating for the company in a research note on Friday, June 12th. Weiss Ratings cut shares of National Health Investors from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, June 12th. Finally, BMO Capital Markets dropped their price objective on shares of National Health Investors from $90.00 to $80.00 and set an “outperform” rating on the stock in a research note on Monday, June 15th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.86.

National Health Investors Stock Performance

Shares of National Health Investors stock opened at $80.05 on Friday. The stock has a market cap of $3.88 billion, a PE ratio of 25.82, a price-to-earnings-growth ratio of 3.59 and a beta of 0.51. The business has a fifty day simple moving average of $74.90 and a 200-day simple moving average of $79.71. The company has a quick ratio of 8.20, a current ratio of 8.20 and a debt-to-equity ratio of 0.83. National Health Investors, Inc. has a 12 month low of $67.94 and a 12 month high of $91.38.

National Health Investors Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.92 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.68 dividend on an annualized basis and a dividend yield of 4.6%. National Health Investors’s dividend payout ratio (DPR) is 118.71%.

National Health Investors Company Profile

National Health Investors, Inc (NYSE: NHI) is a specialized real estate investment trust (REIT) focused on owning and financing high-quality healthcare and senior housing facilities in the United States. The company’s portfolio encompasses a diverse range of properties, including skilled nursing centers, assisted living and memory care communities, behavioral health facilities, dialysis clinics, and medical office buildings. NHI typically enters into long-term net-lease agreements with experienced healthcare operators, providing stable and predictable rental income streams while enabling its tenants to concentrate on delivering quality care.

Since its founding in 1991 and initial public offering later that year, National Health Investors has pursued a disciplined growth strategy centered on strategic acquisitions, joint ventures, and selective development.